Bruce E. Gerhardt, CPA
Mr. Gerhardt joined the Biocept Board in 2010 and serves as the board chair. He has extensive experience and expertise in financial, accounting, and tax matters. He is a tax and business advisor for businesses and high net-worth individuals. Prior to joining Biocept, he was a financial vice-president with several companies and also previously worked for KPMG. Mr. Gerhardt is a graduate of the University of Southern California and is a member of the American Institute of Certified Public Accountants.
Marsha A. Chandler, Ph.D.
Board Vice Chair
Dr. Chandler joined the Biocept Board in 2013 and serves as the board vice chair and chair of the nominating and corporate governance committee. She has extensive experience in organizational management and strategic initiatives. She is Senior Vice Chancellor and Professor Emerita at the School of Global Policy and Strategy at the University of California, San Diego (UCSD). She currently serves as an Advisor to the College of GlobalHealth at Lehigh University, and the Jackson School of Geosciences as well as the College of Pharmaceutical Sciences at the University of Texas at Austin. Dr. Chandler is a member of the Board of Directors of the Corporate Directors Forum. Dr. Chandler previously served as the Executive Vice-President and Chief Operating Officer of the Salk Institute for Biological Studie and as the Senior Vice Chancellor for Academic Affairs at UCSD. Dr. Chandler is a Fellow of the Royal Society of Canada. Dr. Chandler received her Ph.D. from The University of North Carolina at Chapel Hill and has completed the Advanced Management Program at Harvard Business School.
Director, President and CEO
Mr. Morales is the President, CEO, and a member of the Biocept Board, bringing more than 30 years of broad leadership experience in the US and Latin America. He has served in multiple senior management or consulting roles with various Fortune 100 companies including Citibank, Bank of America, Arthur Andersen, Mazda North America, and McDonald’s. Mr. Morales was Business Head of Citibank’s consumer finance operation for Latin America and most recently served as president and CEO of Apoyo Financiero, Inc. a Community Development Financial Institution (CDFI). Mr. Morales has led multiple venture capital and private equity backed start-up companies. He earned his Bachelor of Science degree in Finance from the University of Southern California and is a licensed Certified Public Accountant.
Ms. Rubinstein serves as the chair of Biocept’s compensation committee. She is the CFO of Adverum Biotechnologies and consulting CFO of Medikine, and has been a partner at FLG Partners since 2010. She has over 35 years of operational, financial and capital markets experience and has been CFO of numerous public and private companies. While at FLG, Ms. Rubinstein has served as the permanent or interim CFO of Alector, Apexigen, ArmaGen, Five Prime, Ingenuity, iPierian, Kezar, PaxVax, Retrotope, Sublimity, True North and Tunitas, among others. Ms. Rubinstein also has held various positions at life science companies and investment banks, including Solexa, a public genetic analysis instrumentation company, ChemoCentryx, a biotechnology company, RDJ Advisors, a financial and strategic consulting firm, and Lehman Brothers. Ms. Rubinstein received her M.A. and B.A. degrees in Economics from the University of California, Los Angeles.
Quyen Dao-Haddock, CPA
Ms. Dao-Haddock serves as the chair of Biocept’s audit committee. She is currently the Controller of IQHQ, Inc and a member of the Audit and Compliance committee of Sharp Healthcare. She is a certified public accountant (CPA) with more than 20 years of financial and accounting experience including overseeing technical accounting, budgeting, forecasting, financial modeling, cash management, and SEC reporting. Previously, she was Corporate Controller of American Assets Trust, Inc., an NYSE-listed REIT and was Controller at Pacific Corporate Group, LLC, a private equity firm. She began her career at KPMG LLP. Ms. Dao-Haddock received a BS in Business Administration, Accounting from San Diego State University.
Ivor Royston, M.D.
Dr. Royston is the chair of Biocept’s science and technology committee. He has served as President, Chief Executive Officer, and Director of Viracta since 2015. From 1990 to 2017, Dr. Royston was a Managing Partner of Forward Ventures, a life science venture capital firm. He also previously held the position of Chief Executive Officer of the Sidney Kimmel Cancer Center and was the Director of Clinical Immunology at University of California, San Diego Cancer Center. Dr. Royston was the co-founder of Hybritech, Inc., which developed the PSA test for prostate cancer; and the co-founder of IDEC Corporation, which developed Rituxan, the first approved monoclonal antibody therapy for lymphoma, and which subsequently merged with Biogen to form Biogen Idec, now Biogen. Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University.